Pharmacia & Upjohn has decided not to proceed with the development ofCY1748, Cytel Corp's drug candidate for treating deep vein thrombosis. As a result, Cytel says it intends to seek another commercial partner to sponsor the clinical development of CY1748.
Cytel adds that P&U's decision was based on the outcome of a strategic review of its consolidated development pipeline, and does not reflect any negative preclinical data with respect to the compound's potential safety or efficacy. "Obviously, we were disappointed to learn about P&U's decision," commented Cytel's executive vice president and chief operating officer Robert Roe, "but we also understand that mergers necessitate realignment of development priorities."
CY1748 is a humanized monoclonal antibody specific for P-selection adhesion molecules on platelets. By inhibiting the interaction of platelets with neutrophils, it has been shown in preclinical animal models to reduce the formation of blood clots in veins.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze